JP2017538441A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017538441A5 JP2017538441A5 JP2017540960A JP2017540960A JP2017538441A5 JP 2017538441 A5 JP2017538441 A5 JP 2017538441A5 JP 2017540960 A JP2017540960 A JP 2017540960A JP 2017540960 A JP2017540960 A JP 2017540960A JP 2017538441 A5 JP2017538441 A5 JP 2017538441A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- binding fragment
- variable region
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims description 94
- 102000036639 antigens Human genes 0.000 claims description 94
- 108091007433 antigens Proteins 0.000 claims description 94
- 239000012634 fragment Substances 0.000 claims description 89
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 31
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 28
- 229920001184 polypeptide Polymers 0.000 claims description 28
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 28
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 28
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 27
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 17
- 238000000338 in vitro Methods 0.000 claims description 15
- 210000004027 cell Anatomy 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 230000004064 dysfunction Effects 0.000 claims description 9
- 208000035473 Communicable disease Diseases 0.000 claims description 7
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000013598 vector Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 230000003915 cell function Effects 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- 230000017274 T cell anergy Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 231100000433 cytotoxic Toxicity 0.000 claims description 2
- 230000001472 cytotoxic effect Effects 0.000 claims description 2
- 239000000032 diagnostic agent Substances 0.000 claims description 2
- 229940039227 diagnostic agent Drugs 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 230000001747 exhibiting effect Effects 0.000 claims description 2
- 230000011664 signaling Effects 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims 3
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000013160 medical therapy Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1419094.6A GB201419094D0 (en) | 2014-10-27 | 2014-10-27 | Anti-TIM-3-antibodies |
| GB1419094.6 | 2014-10-27 | ||
| PCT/SG2015/050414 WO2016068802A1 (en) | 2014-10-27 | 2015-10-27 | Anti-tim-3 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017538441A JP2017538441A (ja) | 2017-12-28 |
| JP2017538441A5 true JP2017538441A5 (enExample) | 2018-12-13 |
| JP6719477B2 JP6719477B2 (ja) | 2020-07-08 |
Family
ID=52103462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017540960A Active JP6719477B2 (ja) | 2014-10-27 | 2015-10-27 | 抗ｔｉｍ−３抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10435466B2 (enExample) |
| EP (1) | EP3212229A4 (enExample) |
| JP (1) | JP6719477B2 (enExample) |
| KR (1) | KR20170070241A (enExample) |
| CN (1) | CN107530420B (enExample) |
| AU (1) | AU2015340055A1 (enExample) |
| CA (1) | CA2965627A1 (enExample) |
| GB (1) | GB201419094D0 (enExample) |
| SG (1) | SG11201703346PA (enExample) |
| WO (1) | WO2016068802A1 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3105252B1 (en) * | 2014-02-12 | 2019-07-24 | Michael Uhlin | Bispecific antibodies for use in stem cell transplantation |
| GB201419094D0 (en) | 2014-10-27 | 2014-12-10 | Agency Science Tech & Res | Anti-TIM-3-antibodies |
| SG11201703403TA (en) | 2014-10-27 | 2017-05-30 | Agency Science Tech & Res | Anti-tim-3 antibodies |
| SG10201909173PA (en) | 2015-04-01 | 2019-11-28 | Anaptysbio Inc | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) |
| MA45123A (fr) | 2016-05-27 | 2019-04-10 | Agenus Inc | Anticorps anti-tim-3 et leurs méthodes d'utilisation |
| BR112018076260A2 (pt) | 2016-06-20 | 2019-03-26 | Kymab Limited | anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina |
| AU2017297506A1 (en) | 2016-07-14 | 2019-02-21 | Bristol-Myers Squibb Company | Antibodies against TIM3 and uses thereof |
| JOP20190013A1 (ar) * | 2016-08-25 | 2019-01-31 | Lilly Co Eli | أجسام مضادة لـ (تي آي ام -3) |
| WO2018071345A1 (en) * | 2016-10-11 | 2018-04-19 | Integrated Biotherapeutics, Inc. | Broadly neutralizing antibody targeting the ebolavirus glycoprotein internal fusion loop |
| EP3689419A1 (en) | 2016-11-01 | 2020-08-05 | AnaptysBio, Inc. | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) |
| EP3565598A4 (en) * | 2017-01-03 | 2020-10-28 | Trellis Bioscience, LLC | NATIVE HUMAN ANTIBODIES FOR TIM-3 AND B7-H3 IMMUNE CHECKPOINT MODULATION TARGETS |
| CN110382000A (zh) | 2017-01-09 | 2019-10-25 | 泰萨罗公司 | 用抗tim-3抗体治疗癌症的方法 |
| EP3658185A4 (en) | 2017-07-28 | 2021-07-14 | Phanes Therapeutics, Inc. | ANTI-TIM-3 ANTIBODIES AND USES THEREOF |
| WO2019046321A1 (en) | 2017-08-28 | 2019-03-07 | Bristol-Myers Squibb Company | TIM-3 ANTAGONISTS FOR THE TREATMENT AND DIAGNOSIS OF CANCERS |
| CN118373912A (zh) | 2017-11-10 | 2024-07-23 | 新加坡科技研究局 | IL2Rβ/共同γ链抗体 |
| KR102813913B1 (ko) | 2018-01-12 | 2025-05-30 | 브리스톨-마이어스 스큅 컴퍼니 | Tim3에 대한 항체 및 그의 용도 |
| WO2019143607A1 (en) | 2018-01-16 | 2019-07-25 | Bristol-Myers Squibb Company | Methods of treating cancer with antibodies against tim3 |
| WO2019165982A1 (en) | 2018-02-28 | 2019-09-06 | WuXi Biologics Ireland Limited | Monoclonal antibody against human lag-3, method for preparing same, and use thereof |
| EP3768725A4 (en) * | 2018-03-20 | 2021-06-02 | Wuxi Biologics Ireland Limited | NEW ANTI-TIM-3 ANTIBODIES |
| CN110305216B (zh) * | 2018-03-20 | 2022-09-02 | 无锡智康弘义生物科技有限公司 | 新型抗tim-3抗体 |
| JP7351845B2 (ja) | 2018-03-23 | 2023-09-27 | ブリストル－マイヤーズ スクイブ カンパニー | Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用 |
| KR20210035805A (ko) | 2018-06-15 | 2021-04-01 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가 |
| WO2020094836A1 (en) | 2018-11-09 | 2020-05-14 | Euchloe Bio Pte. Ltd. | Il2rbeta/common gamma chain antibodies |
| WO2020094834A1 (en) | 2018-11-09 | 2020-05-14 | Euchloe Bio Pte. Ltd. | Il2rbeta/common gamma chain antibodies |
| CN111320690B (zh) * | 2018-12-17 | 2022-04-05 | 程联胜 | 一种抗人Tim3单克隆抗体及其应用 |
| MA55805A (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
| JP2022534982A (ja) | 2019-05-30 | 2022-08-04 | ブリストル－マイヤーズ スクイブ カンパニー | 細胞局在化シグネチャーおよびその使用 |
| US20220363760A1 (en) | 2019-05-30 | 2022-11-17 | Bristol-Myers Squibb Company | Multi-tumor gene signature for suitability to immuno-oncology therapy |
| WO2020243570A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
| CN113164601B (zh) * | 2019-09-19 | 2023-09-29 | 上药生物治疗（香港）有限公司 | 一种分离的抗原结合蛋白及其用途 |
| US20230114107A1 (en) | 2019-12-17 | 2023-04-13 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| US20230355804A1 (en) | 2020-06-29 | 2023-11-09 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| EP4204453A1 (en) | 2020-08-31 | 2023-07-05 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| RS66849B1 (sr) | 2020-12-28 | 2025-06-30 | Bristol Myers Squibb Co | Kompozicije antitela i postupci njihove upotrebe |
| US20220233689A1 (en) | 2020-12-28 | 2022-07-28 | Bristol-Myers Squibb Company | Methods of treating tumors |
| MX2023009100A (es) | 2021-02-03 | 2023-09-25 | Mozart Therapeutics Inc | Agentes aglutinantes y métodos para usar los mismos. |
| CA3214085A1 (en) | 2021-03-31 | 2022-10-06 | Darby Rye Schmidt | Thanotransmission polypeptides and their use in treating cancer |
| US20240376224A1 (en) | 2021-04-02 | 2024-11-14 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| KR20240026507A (ko) | 2021-06-29 | 2024-02-28 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도 |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| KR20240159621A (ko) | 2022-03-18 | 2024-11-05 | 브리스톨-마이어스 스큅 컴퍼니 | 폴리펩티드를 단리하는 방법 |
| AU2023281061A1 (en) | 2022-06-02 | 2024-12-05 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| WO2024163477A1 (en) | 2023-01-31 | 2024-08-08 | University Of Rochester | Immune checkpoint blockade therapy for treating staphylococcus aureus infections |
| WO2025038763A1 (en) | 2023-08-15 | 2025-02-20 | Bristol-Myers Squibb Company | Ceramic hydroxyapatite chromatography flow through method |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2258726A1 (en) | 1995-06-14 | 2010-12-08 | The Regents of the University of California | High affinity human antibodies to c-erbB-2 |
| US20030103978A1 (en) | 2000-02-23 | 2003-06-05 | Amgen Inc. | Selective binding agents of osteoprotegerin binding protein |
| ES2192426B1 (es) | 2000-05-11 | 2005-02-16 | Universidad De Vigo | Anticuerpo monoclonal humano sm50/20 que reconoce leucocitos humanos, y su uso en terapia. |
| JP4754219B2 (ja) | 2002-12-02 | 2011-08-24 | アムジエン・フレモント・インコーポレイテツド | 腫瘍壊死因子を対象とする抗体、およびそれらの使用 |
| JP2007525434A (ja) | 2003-03-19 | 2007-09-06 | アブジェニックス インコーポレイテッド | Ｔ細胞、免疫グロブリンドメインおよびムチンドメイン１（ｔｉｍ−１）抗原に対する抗体およびその使用。 |
| BRPI0414924A (pt) * | 2003-10-03 | 2006-11-07 | Brigham & Womens Hospital | ligantes de tim-3 e seus métodos |
| PT2100614E (pt) | 2005-06-17 | 2013-12-16 | Imclone Llc | Antagonistas de receptor para tratamento de cancro ósseo metastático |
| CA2629453C (en) | 2005-11-10 | 2018-03-06 | Curagen Corporation | Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen |
| US9000131B2 (en) | 2008-07-31 | 2015-04-07 | The Regents Of The University Of California | Antibodies that neutralize botulinum neurotoxins |
| EP2356270B1 (en) | 2008-11-07 | 2016-08-24 | Fabrus Llc | Combinatorial antibody libraries and uses thereof |
| US8647623B2 (en) * | 2009-04-10 | 2014-02-11 | Kyowa Hakko Kirin Co., Ltd | Method for treatment of blood tumor using anti-TIM-3 antibody |
| JP2013523184A (ja) | 2010-04-15 | 2013-06-17 | アムジエン・インコーポレーテツド | ヒトＦＧＦ受容体およびβ−ＫＬＯＴＨＯ結合性タンパク質 |
| HUE040213T2 (hu) * | 2010-06-11 | 2019-02-28 | Kyowa Hakko Kirin Co Ltd | Anti-TIM antitest |
| US9163087B2 (en) * | 2010-06-18 | 2015-10-20 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions |
| WO2012092539A2 (en) | 2010-12-31 | 2012-07-05 | Takeda Pharmaceutical Company Limited | Antibodies to dll4 and uses thereof |
| US8841418B2 (en) | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
| CN102392038B (zh) | 2011-11-01 | 2013-04-17 | 浙江大学 | 一种删除转基因水稻精米中的外源基因的表达载体及其应用 |
| CN102492038B (zh) | 2011-12-09 | 2014-05-28 | 中国人民解放军军事医学科学院基础医学研究所 | 抗人Tim-3的中和性单克隆抗体L3D及其用途 |
| CA2916638C (en) | 2012-07-31 | 2021-01-12 | The Brigham And Women's Hospital, Inc. | Modulation of the immune response |
| WO2014070874A1 (en) | 2012-10-31 | 2014-05-08 | The Brigham And Women's Hospital, Inc. | Methods for modulating immune responses during chronic immune conditions by targeting il-27 induced pathways |
| EP2948475A2 (en) * | 2013-01-23 | 2015-12-02 | AbbVie Inc. | Methods and compositions for modulating an immune response |
| JP2014162739A (ja) * | 2013-02-22 | 2014-09-08 | National Institute Of Biomedical Innovation | 二重特異性抗体及び医薬組成物 |
| ES2923641T3 (es) | 2013-12-30 | 2022-09-29 | Epimab Biotherapeutics Inc | Inmunoglobulina con Fabs en tándem y usos de la misma |
| CN103936853B (zh) * | 2014-01-26 | 2016-08-17 | 中国人民解放军军事医学科学院基础医学研究所 | 一种检测tim-3试剂盒及其使用方法 |
| JOP20200096A1 (ar) * | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| GB201419094D0 (en) | 2014-10-27 | 2014-12-10 | Agency Science Tech & Res | Anti-TIM-3-antibodies |
| SG11201703403TA (en) | 2014-10-27 | 2017-05-30 | Agency Science Tech & Res | Anti-tim-3 antibodies |
| CN104592388B (zh) | 2015-03-02 | 2017-05-31 | 中国人民解放军总医院 | 一种抗人Tim‑3的单克隆抗体的抗原结合部分 |
-
2014
- 2014-10-27 GB GBGB1419094.6A patent/GB201419094D0/en not_active Ceased
-
2015
- 2015-10-27 JP JP2017540960A patent/JP6719477B2/ja active Active
- 2015-10-27 CN CN201580071388.7A patent/CN107530420B/zh active Active
- 2015-10-27 EP EP15854404.9A patent/EP3212229A4/en not_active Withdrawn
- 2015-10-27 KR KR1020177014162A patent/KR20170070241A/ko not_active Withdrawn
- 2015-10-27 AU AU2015340055A patent/AU2015340055A1/en not_active Abandoned
- 2015-10-27 SG SG11201703346PA patent/SG11201703346PA/en unknown
- 2015-10-27 CA CA2965627A patent/CA2965627A1/en not_active Abandoned
- 2015-10-27 US US15/521,514 patent/US10435466B2/en active Active
- 2015-10-27 WO PCT/SG2015/050414 patent/WO2016068802A1/en not_active Ceased
-
2019
- 2019-08-27 US US16/551,944 patent/US20200055935A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017538441A5 (enExample) | ||
| JP2017536111A5 (enExample) | ||
| JP2018500924A5 (enExample) | ||
| JP2019519208A5 (enExample) | ||
| JP2018508475A5 (enExample) | ||
| JP2018527912A5 (enExample) | ||
| US9574014B2 (en) | Chimeric antigen receptor compositions | |
| ES2585702T3 (es) | Composiciones y métodos para la unión al ácido lisofosfatídico | |
| RU2017116847A (ru) | Антитела к pd-1 | |
| JP2017029157A5 (enExample) | ||
| JP2019511222A5 (enExample) | ||
| JP2020040969A5 (enExample) | ||
| JP2016505240A5 (enExample) | ||
| FI3250592T3 (fi) | Transtyretiinin vastaisia vasta-aineita | |
| CN118853594A (zh) | 嵌合痘病毒组合物及其用途 | |
| JP2014509841A5 (enExample) | ||
| JP2018508215A5 (enExample) | ||
| JP2013165711A5 (enExample) | ||
| JP2021100408A (ja) | 自己免疫疾患の治療及び／又は診断におけるアプタマーの使用 | |
| JP2019530431A5 (enExample) | ||
| JP2019535241A5 (enExample) | ||
| JP2021500406A5 (enExample) | ||
| JP2019530728A5 (enExample) | ||
| JP2014510519A5 (enExample) | ||
| CN111388664A (zh) | 干细胞增强疗法 |